Artiva Biotherapeutics, Inc. (ARTV) shareholders
Close on Nov 17, 2026Market cap $188.72MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (37.90%), Rajeev Shah (37.90%) and 1 more | 18,415,956 | 37.90% | 13D (active) amendment | Jul 22, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (36.60%), Peter Kolchinsky (36.60%) and 1 more | 17,811,623 | 36.60% | 13D (active) amendment | Jun 11, 2026 |
| GC Corp Joint filing with Yong-Jun Huh (12.30%) | 5,999,703 | 12.30% | 13D (active) amendment | May 11, 2026 |
| Viking Global Opportunities Parent GP LLC Joint filing with Viking Global Investors LP (5.40%), Halvorsen Ole Andreas (5.40%) and 1 more | 2,604,166 | 5.40% | 13G (passive) | May 11, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARTV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,955,642 | 36.73% | $174.17M | +8,102,340 | 1.51% |
| Viking Global Investors LP | 2,604,166 | 5.33% | $25.26M | New | 0.07% |
| Blackstone Inc. | 2,403,437 | 4.92% | $23.31M | New | 0.07% |
| 5AM Venture Management, LLC | 2,353,304 | 4.81% | $22.83M | – | 7.93% |
| VR Adviser, LLC | 2,043,596 | 4.18% | $19.82M | +434,027 | 0.60% |
| Franklin Resources Inc | 1,997,223 | 4.09% | $19.37M | +1,476,896 | 0.00% |
| Caligan Partners LP | 1,736,111 | 3.55% | $16.84M | New | 0.79% |
| Vanguard Capital Management LLC | 981,815 | 2.01% | $9.52M | +774,129 | 0.00% |
| Samsara BioCapital, LLC | 954,861 | 1.95% | $9.26M | New | 0.76% |
| Blue Owl Capital Holdings LP | 874,542 | 1.79% | $8.48M | New | 1.28% |
| Propel Bio Management, LLC | 696,436 | 1.42% | $6.76M | +550,067 | 3.54% |
| BlackRock, Inc. | 694,726 | 1.42% | $6.74M | +481,338 | 0.00% |
| Citadel Advisors LLC | 609,376 | 1.25% | $5.91M | +593,506 | 0.00% |
| Nantahala Capital Management, LLC | 600,000 | 1.23% | $5.82M | New | 0.10% |
| Silverarc Capital Management, LLC | 525,000 | 1.07% | $5.09M | New | 0.53% |
| Geode Capital Management, LLC | 353,845 | 0.72% | $3.43M | +252,150 | 0.00% |
| Boothbay Fund Management, LLC | 314,375 | 0.64% | $3.05M | New | 0.04% |
| Revelation Capital Management, LLC | 299,311 | 0.61% | $2.90M | – | 2.65% |
| Alyeska Investment Group, L.P. | 273,615 | 0.56% | $2.65M | +173,615 | 0.01% |
| Acuta Capital Partners, LLC | 260,416 | 0.53% | $2.53M | New | 1.76% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 41M | 83.2% | 39 / 25 | 2 / 7 | 25M | 1M |
| Q1 2026 | 40 | 17M | 34.4% | 12 / 3 | 12 / 5 | 1M | 0M |
| Q4 2025 | 34 | 17M | 34.7% | 6 / 4 | 15 / 12 | 1M | 2M |
| Q3 2025 | 40 | 18M | 37.1% | 6 / 8 | 16 / 14 | 1M | 1M |
| Q2 2025 | 48 | 19M | 37.9% | 12 / 9 | 16 / 17 | 1M | 3M |
| Q1 2025 | 53 | 21M | 42.8% | 4 / 22 | 12 / 7 | 1M | 1M |
| Q4 2024 | 57 | 21M | 43.3% | 9 / 18 | 6 / 1 | 0M | 0M |
| Q3 2024 | 49 | 21M | 42.4% | 49 / 0 | 0 / 0 | 21M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
50 funds held ARTV in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARTV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 699,899 | 1.43% | $6.79M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 542,371 | 1.11% | $5.48M | 0.47% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 456,468 | 0.93% | $4.61M | 0.19% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 269,149 | 0.55% | $2.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 140,593 | 0.29% | $1.36M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 101,355 | 0.21% | $983.14K | 1.27% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 51,557 | 0.11% | $520.73K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Fund | 50,000 | 0.10% | $485.00K | 0.49% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 35,000 | 0.07% | $339.50K | 0.23% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 30,895 | 0.06% | $245.00K | 0.00% | May 31, 2026 |
| U.S. Micro Cap Portfolio | 27,426 | 0.06% | $277.00K | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 23,015 | 0.05% | $223.25K | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 20,825 | 0.04% | $202.00K | 0.00% | Jun 30, 2026 |
| Nationwide Bailard Small Cap Value Fund | 20,700 | 0.04% | $209.07K | 0.16% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 16,258 | 0.03% | $128.93K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Fred Aslan | Chief Executive Officer, Director | 1,457,428 | 2.98% | Nov 3, 2026 |
| Subhashis Banerjee | Chief Medical Officer | 168,738 | 0.35% | Nov 3, 2026 |
| Jennifer Bush | COO, CLO, Compliance Officer | 357,720 | 0.73% | Nov 3, 2026 |
| Christopher Horan | Chief Tech Operations Officer | 302,321 | 0.62% | Nov 3, 2026 |
| Gines Diego Miralles | President & Head of R&D | 122,500 | 0.25% | Sep 11, 2026 |
| Heather Raymon | SVP, Research and Development | 148,228 | 0.30% | May 19, 2026 |
| Thad Allen Huston | Chief Financial Officer | 220,000 | 0.45% | Mar 10, 2026 |
| Neha Krishnamohan | Chief Financial Officer | 99,356 | 0.20% | Nov 17, 2025 |
| Thorsten Graef | Chief Medical Officer | 80,000 | 0.16% | Feb 28, 2025 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 17,329,570 | 35.45% | Sep 14, 2026 |
| Alison Moore | Director | – | – | Sep 14, 2026 |
| Elaine K. Sorg | Director | – | – | Sep 14, 2026 |
| Brian Daniels | Director | – | – | Sep 14, 2026 |
| Rajeev M. Shah | Director, 10% owner | 16,817,573 | 34.40% | Sep 14, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 17,283,802 | 35.35% | Sep 14, 2026 |
| Peter Kolchinsky | Director, 10% owner | 17,242,483 | 35.27% | Sep 14, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 16,817,543 | 34.40% | Sep 14, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 16,795,919 | 34.35% | Sep 14, 2026 |
| Daniel G. Baker | Director | – | – | Sep 14, 2026 |
| Laura Stoppel | Director | – | – | Sep 14, 2026 |
| Elizabeth L. Hougen | Director | – | – | Sep 14, 2026 |
| Corp. GC | 10% owner | 5,999,703 | 12.27% | May 28, 2026 |
| Cell Corp GC | 10% owner | 1,541,371 | 3.15% | May 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher Horan Chief Tech Operations Officer | Nov 2, 2026 | Sale | −10,423 | $4.18 | $43.58K | 302,321 |
| Jennifer Bush COO, CLO, Compliance Officer | Nov 2, 2026 | Sale | −8,439 | $4.18 | $35.28K | 357,720 |
| Subhashis Banerjee Chief Medical Officer | Nov 2, 2026 | Sale | −1,110 | $4.18 | $4.64K | 168,738 |
| Fred Aslan Chief Executive Officer, Director | Nov 2, 2026 | Sale | −62,178 | $4.18 | $259.97K | 1,457,428 |
| Fred Aslan Chief Executive Officer, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −23,463 | $7.20 | $168.88K | 1,519,606 |
| Christopher Horan Chief Tech Operations Officer | Oct 5, 2026 | Sale | −10,340 | $6.84 | $70.70K | 312,744 |
| Jennifer Bush COO, CLO, Compliance Officer | Oct 5, 2026 | Sale | −8,370 | $6.84 | $57.23K | 366,159 |
| Subhashis Banerjee Chief Medical Officer | Oct 5, 2026 | Sale | −1,099 | $6.84 | $7.51K | 169,848 |
| Fred Aslan Chief Executive Officer, Director | Oct 5, 2026 | Sale | −61,696 | $6.84 | $421.83K | 1,543,069 |
| Fred Aslan Chief Executive Officer, Director | Sep 15, 2026 | Award | +110,000 | – | – | 1,604,765 |
| Fred Aslan Chief Executive Officer, Director | Sep 10, 2026 | Award | +45,000 | – | – | 1,494,765 |
| Gines Diego Miralles President & Head of R&D | Sep 9, 2026 | Award | +45,000 | – | – | 122,500 |
| Subhashis Banerjee Chief Medical Officer | Sep 9, 2026 | Award | +30,000 | – | – | 170,947 |
| Christopher Horan Chief Tech Operations Officer | Sep 9, 2026 | Award | +40,000 | – | – | 323,084 |
| Jennifer Bush COO, CLO, Compliance Officer | Sep 9, 2026 | Award | +45,000 | – | – | 374,529 |
| Fred Aslan Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −23,429 | $10.92 | $255.84K | 1,449,765 |
| Jennifer Bush COO, CLO, Compliance Officer | Sep 3, 2026 | Sale | −8,391 | $11.16 | $93.64K | 329,529 |
| Subhashis Banerjee Chief Medical Officer | Sep 3, 2026 | Sale | −1,100 | $11.16 | $12.28K | 140,947 |
| Christopher Horan Chief Tech Operations Officer | Sep 3, 2026 | Sale | −10,366 | $11.16 | $115.68K | 283,084 |
| Fred Aslan Chief Executive Officer, Director | Sep 3, 2026 | Sale | −61,888 | $11.16 | $690.67K | 1,473,194 |
| Subhashis Banerjee Chief Medical Officer | Aug 27, 2026 | Sale(10b5-1 plan) | −8,222 | $12.01 | $98.75K | 142,047 |
| Subhashis Banerjee Chief Medical Officer | Aug 27, 2026 | Option exercise | +5,306 | $1.92 | $10.19K | 150,269 |
| Subhashis Banerjee Chief Medical Officer | Aug 18, 2026 | Option exercise | +429 | $1.92 | $824 | 145,392 |
| Subhashis Banerjee Chief Medical Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −429 | $12.00 | $5.15K | 144,963 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 31, 2026 | Buy | +24,944 | $9.93 | $247.69K | 17,329,570 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 29, 2026 | Buy | +20,824 | $9.99 | $208.03K | 17,304,626 |
| RA Capital Nexus Fund III, L.P. Director | Jul 24, 2026 | Buy | +41,319 | $9.99 | $412.78K | 17,283,802 |
| Peter Kolchinsky Director, 10% owner | Jul 23, 2026 | Buy | +59,880 | $9.96 | $596.40K | 17,242,483 |
| Peter Kolchinsky Director, 10% owner | Jul 22, 2026 | Buy | +84,124 | $9.93 | $835.35K | 17,182,603 |
| Peter Kolchinsky Director, 10% owner | Jul 21, 2026 | Buy | +120,582 | $9.55 | $1.15M | 17,098,479 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 17, 2026 | Buy | +7,882 | $8.95 | $70.54K | 16,977,927 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 16, 2026 | Buy | +152,472 | $8.93 | $1.36M | 16,970,045 |
| RA Capital Nexus Fund, L.P. Director | Jul 13, 2026 | Buy | +6,522 | $8.94 | $58.31K | 16,817,543 |
| Rajeev M. Shah Director, 10% owner | Jul 13, 2026 | Buy | +6,552 | $8.94 | $58.57K | 16,817,573 |
| Rajeev M. Shah Director, 10% owner | Jul 10, 2026 | Buy | +15,102 | $8.97 | $135.46K | 16,811,021 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 26, 2026 | Buy | +1,876 | $8.98 | $16.85K | 16,795,919 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 25, 2026 | Buy | +31,000 | $8.88 | $275.28K | 16,794,043 |
| Peter Kolchinsky Director, 10% owner | Jun 16, 2026 | Buy | +124,893 | $8.89 | $1.11M | 16,763,043 |
| Peter Kolchinsky Director, 10% owner | Jun 15, 2026 | Buy | +15,414 | $8.99 | $138.57K | 16,638,150 |
| Peter Kolchinsky Director, 10% owner | Jun 12, 2026 | Buy | +391,019 | $8.57 | $3.35M | 16,622,736 |
| RA Capital Nexus Fund, L.P. Director | Jun 11, 2026 | Buy | +548,580 | $7.91 | $4.34M | 16,231,717 |
| RA Capital Nexus Fund, L.P. Director | Jun 10, 2026 | Buy | +103 | $7.00 | $721 | 15,683,137 |
| RA Capital Nexus Fund, L.P. Director | Jun 9, 2026 | Buy | +479,039 | $6.91 | $3.31M | 15,683,034 |
| Fred Aslan Chief Executive Officer, Director | May 19, 2026 | Sale | −27,116 | $9.01 | $244.32K | 1,535,082 |
| Christopher Horan Chief Tech Operations Officer | May 19, 2026 | Sale | −7,002 | $9.01 | $63.09K | 293,450 |
| Jennifer Bush COO, CLO, Compliance Officer | May 19, 2026 | Sale | −8,790 | $9.01 | $79.20K | 337,920 |
| Heather Raymon SVP, Research and Development | May 19, 2026 | Sale | −3,095 | $9.01 | $27.89K | 148,228 |
| Subhashis Banerjee Chief Medical Officer | May 19, 2026 | Sale | −7,037 | $9.01 | $63.40K | 144,963 |
| Gines Diego Miralles President & Head of R&D | May 18, 2026 | Award | +77,500 | – | – | 77,500 |
| Corp. GC 10% owner | May 11, 2026 | Buy | +347,222 | $11.52 | $4.00M | 1,607,734 |
| Corp. GC 10% owner | May 11, 2026 | Buy | +1,085,069 | $11.52 | $12.50M | 4,391,969 |
| RA Capital Nexus Fund III, L.P. Director | May 11, 2026 | Buy | +6,510,416 | $11.52 | $75.00M | 15,203,995 |
| Thad Allen Huston Chief Financial Officer | Mar 10, 2026 | Award | +220,000 | – | – | 220,000 |
| Subhashis Banerjee Chief Medical Officer | Feb 15, 2026 | Award | +102,000 | – | – | 152,000 |
| Jennifer Bush COO, CLO, Secy, Compliance Off | Feb 15, 2026 | Tax withholding | −3,515 | $4.00 | $14.06K | 346,710 |
| Jennifer Bush COO, CLO, Secy, Compliance Off | Feb 15, 2026 | Award | +117,300 | – | – | 350,225 |
| Christopher Horan Chief Tech Operations Officer | Feb 15, 2026 | Award | +117,300 | – | – | 302,639 |
| Christopher Horan Chief Tech Operations Officer | Feb 15, 2026 | Tax withholding | −2,187 | $4.00 | $8.75K | 300,452 |
| Fred Aslan President and CEO, Director | Feb 15, 2026 | Award | +366,850 | – | – | 1,576,798 |
| Fred Aslan President and CEO, Director | Feb 15, 2026 | Tax withholding | −14,600 | $4.00 | $58.40K | 1,562,198 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Artiva Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,516 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Fred Aslan Director, Officer | Oct 6, 2026 | 34,465 | $245.74K | Oct 6, 2026 | Restricted Stock Units |
| Fred Aslan Director, Officer | Sep 8, 2026 | 23,429 | $262.17K | Sep 8, 2026 | Restricted Stock Units |
| Subhashis Banerjee Officer | Aug 27, 2026 | 7,818 | $92.02K | Aug 27, 2026 | Exercise of Stock Options |
| Subhashis Banerjee Officer | Aug 18, 2026 | 833 | $9.78K | Aug 18, 2026 | Exercise of Stock Options |
| Fred Aslan Officer, Director | May 18, 2026 | 28,000 | $258.16K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Subhashis Banerjee Officer, Director | May 18, 2026 | 7,000 | $64.54K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Jennifer Bush Officer, Director | May 18, 2026 | 9,000 | $82.98K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Christopher Horan Officer, Director | May 18, 2026 | 7,500 | $69.15K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Heather Raymon Officer, Director | May 18, 2026 | 3,500 | $32.27K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Fred Aslan Director, Officer | Dec 15, 2025 | 12,749 | $42.07K | Dec 15, 2025 | Restricted Stock Units |
| Fred Aslan Director, Officer | Nov 17, 2025 | 6,375 | $20.72K | Nov 17, 2025 | Restricted Stock Units |
| Fred Aslan Director, Officer | Oct 17, 2025 | 25,500 | $70.64K | Oct 17, 2025 | Restricted Stock Units |
| Fred Aslan Director, Officer | Aug 15, 2025 | 25,500 | $68.85K | Aug 15, 2025 | Restricted Stock Units |
See a number that looks wrong?